-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Shiyao Group (01093.HK) announced that the phase II clinical trial of the SYS 6026 injection (this product) developed by the Group to treat high-grade cervical squamous intraepithelial lesion (HSIL) related to human papillomavirus (HPV) type 16 or 18 has been officially launched in China.

Zhitongcaijing·07/22/2026 13:17:06
Listen to the news
Zhitong Finance App News, Shiyao Group (01093.HK) announced that the phase II clinical trial of the SYS 6026 injection (this product) developed by the Group to treat high-grade cervical squamous intraepithelial lesion (HSIL) related to human papillomavirus (HPV) type 16 or 18 has been officially launched in China.